Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 84
- Registration Number
- NCT00834834
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa
- Conditions
- Interventions
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 293
- Registration Number
- NCT00733525
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of Minnesota Minneapolis, MN, Minneapolis, Minnesota, United States
🇺🇸University of North Dakota / Neuropsychiatric Research Institute, Fargo, North Dakota, United States
Fluoxetine vs. Brief Psychotherapy for Major Depression
- Conditions
- Interventions
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2008-07-14
- Lead Sponsor
- University of Turku
- Target Recruit Count
- 85
- Registration Number
- NCT00714779
The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 45
- Registration Number
- NCT00678574
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women
- Conditions
- Interventions
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 8
- Registration Number
- NCT00676026
- Locations
- 🇺🇸
Yale University School of Medicine; Yale Program for Women's Reproductive Behavioral Health, New Haven, Connecticut, United States
A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
- Conditions
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2010-06-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT00666757
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States
Fluoxetine on Motor Rehabilitation After Ischemic Stroke
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 100
- Registration Number
- NCT00657163
- Locations
- 🇫🇷
University Hospital René Dubos, Cergy-Pontoise, France
🇫🇷University Hospital Sainte Anne, Paris, France
🇫🇷University Hospital Pitié Salpétrière, Paris, France
Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- TEMPVA Research Group, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00633685
- Locations
- 🇺🇸
Carl R. Darnall Army Medical Center, Ft. Hood, Texas, United States
Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 144
- Registration Number
- NCT00612313
- Locations
- 🇺🇸
Children's Medical Center of Dallas, Outpatient Psychiatry Clinic, Dallas, Texas, United States
Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 83
- Registration Number
- NCT00611975
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.